Using Bleomycin for treating lymphatic malformations in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of Bleomycin in the sclerotherapy of lymphatic malformations (LMs) in pediatric patients. The study aims to compare the efficacy and safety of different concentrations of Bleomycin, which is an anticancer drug, in treating LMs that cannot be surgically removed. LMs are vascular anomalies that can cause significant symptoms and complications, and sclerotherapy offers a less invasive alternative to surgery. The trial will enroll participants under 14 years of age with rapidly progressing LMs that have been confirmed through imaging.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female participants less than 14 years of age at the time of informed consent/assent form was signed.
* Participants whose parents have voluntarily given written consent and participants who provided assent (if applicable) after the study has been explained to them.
* Participants with LMs of all sites measured and confirmed via imaging at screening, with rapid progression, resluting in obvious symptoms or dysfunction, which could not be radically resected and could be treated by sclerotherapy.

Exclusion Criteria:

* Penicillin allergy.
* Vascular tumors or combined vascular malformations.
* Participants who may have had surgical or sclerotherapy treatment by other hardeners.
* LMs growing slowly, without obvious symptoms or dysfunction, which does not need to be treated prematurely.

Where it's running

• West China Hospital of Sichuan University
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Yi Ji, Ph.D.
• Email: jijiyuanyuan@163.com
• Phone: +8618980606865

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry and biobank for lymphatic malformations in Italy

  This study is creating a registry and biobank to collect information and samples from people with lymphatic malformations in Italy to improve understanding and treatment of these rare conditions.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT06892964

• Using sirolimus to treat cystic lymphatic malformations in children

  This study is testing different doses of sirolimus to see if it can safely help children with cystic lymphatic malformations.

  Recruiting Phase 2/3 West China Hospital · Chengdu, Sichuan · NCT06673290

• Using indocyanine green imaging to treat cystic lymphatic malformation in children

  This study tests if using a special imaging technique can help doctors treat cystic lymphatic malformation in children better than traditional surgery alone.

  Recruiting Nanjing Children's Hospital · Nanjing, Jiangsu · NCT06275022

• Targeted therapies for patients with vascular malformations

  This study is testing new targeted treatments for patients with slow-flow and fast-flow vascular malformations to see if they work better than the usual therapies.

  Recruiting at 2 sites Phase 2 Murdoch Childrens Research Institute · Parkville, Victoria and 1 other locations · NCT05983159

• Treatment of lymphatic malformations in children using TARA-002

  This study is testing if a new treatment called TARA-002 can safely help reduce lymphatic malformations in children aged 6 months to under 18 years.

  Recruiting at 9 sites Phase 2 Protara Therapeutics · Birmingham, Alabama and 10 other locations · NCT05871970

• Weekly treatment with sirolimus for venous and lymphatic malformations

  This study is testing if giving sirolimus once a week can help people with venous and lymphatic malformations feel better while causing fewer side effects than taking it every day.

  Recruiting Phase 2 Medical University of South Carolina · Charleston, South Carolina · NCT04861064

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.